Suppliers and packagers for IBUPROFEN

IBUPROFEN

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal Pharms	IBUPROFEN	ibuprofen	CAPSULE;ORAL	202300	ANDA	Dolgencorp, Inc. (DOLLAR GENERAL & REXALL)	55910-830-12	120 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (55910-830-12)	2022-03-16
Amneal Pharms	IBUPROFEN	ibuprofen	CAPSULE;ORAL	202300	ANDA	Dolgencorp, Inc. (DOLLAR GENERAL & REXALL)	55910-830-20	1 BOTTLE, PLASTIC in 1 BOX (55910-830-20) / 20 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC	2022-03-16
Amneal Pharms	IBUPROFEN	ibuprofen	CAPSULE;ORAL	202300	ANDA	Dolgencorp, Inc. (DOLLAR GENERAL & REXALL)	55910-830-21	200 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC (55910-830-21)	2022-03-16
Amneal Pharms	IBUPROFEN	ibuprofen	CAPSULE;ORAL	202300	ANDA	Dolgencorp, Inc. (DOLLAR GENERAL & REXALL)	55910-830-40	1 BOTTLE, PLASTIC in 1 BOX (55910-830-40) / 40 CAPSULE, LIQUID FILLED in 1 BOTTLE, PLASTIC	2022-03-16

Ibuprofen Supply Chain: Key Manufacturers and Patent Landscape

Last updated: February 19, 2026

The global ibuprofen supply chain is characterized by a concentrated group of active pharmaceutical ingredient (API) manufacturers and a complex patent landscape influencing market dynamics. Key players in API production include BASF, SI Group, and Hebei Jiheng Pharmaceutical, with production capacity concentrated in Asia and Europe. Patent expiries for foundational ibuprofen synthesis methods have led to a mature generics market, though ongoing innovation focuses on process optimization and polymorph control.

Who are the Primary Ibuprofen API Manufacturers?

The production of ibuprofen API is dominated by a limited number of large-scale chemical manufacturers. These companies operate highly integrated facilities to ensure cost-efficiency and quality control.

• BASF SE: A German multinational chemical company, BASF is a significant producer of ibuprofen API. Its global manufacturing network and established supply chain infrastructure support its role as a major supplier. The company emphasizes consistent quality and regulatory compliance in its API production [1].
• SI Group: Based in the United States, SI Group is another prominent manufacturer of ibuprofen. The company has invested in optimizing its production processes for efficiency and environmental sustainability. SI Group serves both the prescription and over-the-counter (OTC) ibuprofen markets [2].
• Hebei Jiheng Pharmaceutical Co., Ltd.: This Chinese company is a substantial contributor to the global ibuprofen API supply. Its large production capacity and competitive pricing have made it a key player, particularly in supplying generic pharmaceutical manufacturers. Jiheng Pharmaceutical adheres to international quality standards, including GMP [3].
• IOL Chemicals and Pharmaceuticals Ltd. (IOLCP): An Indian company, IOLCP is one of the world's largest producers of ibuprofen API by volume. The company has focused on backward integration, controlling raw material supply to enhance its cost competitiveness and supply chain reliability [4].
• Sumitomo Chemical Co., Ltd.: While perhaps less dominant in volume compared to others, Sumitomo Chemical, a Japanese conglomerate, also participates in the ibuprofen API market, contributing to global supply with a focus on high-purity products.

Geographically, API production is concentrated in regions with established chemical manufacturing infrastructure and access to raw materials. Asia, particularly China and India, accounts for a significant portion of global ibuprofen API output due to manufacturing cost advantages. Europe, with companies like BASF, also maintains substantial production capabilities, often focusing on higher-value or specialized grades.

What is the Current Ibuprofen Patent Landscape?

The patent landscape for ibuprofen is largely defined by the expiration of patents covering its core synthesis pathways. The original synthesis methods, developed decades ago, are now in the public domain, facilitating widespread generic production. However, innovation continues in specific areas:

• Process Chemistry Improvements: Patents are still filed and granted for novel or significantly improved methods of synthesizing ibuprofen. These patents often focus on:
  • Increased Yield: Developing catalytic systems or reaction conditions that maximize the conversion of starting materials to ibuprofen, reducing waste and cost.
  • Reduced Environmental Impact: Implementing greener chemistry principles, such as using less hazardous solvents, reducing energy consumption, or developing more atom-economical reactions.
  • Streamlined Production: Creating more efficient multi-step syntheses or reducing the number of purification steps.
  • Polymorph Control: Ibuprofen can exist in different crystalline forms (polymorphs), which can affect its physical properties like solubility, dissolution rate, and stability. Patents are often sought for specific, stable, or bioavailable polymorphs and methods to consistently produce them [5].
• Formulation Patents: While not directly related to API synthesis, patents covering specific pharmaceutical formulations of ibuprofen (e.g., extended-release tablets, pediatric suspensions with improved taste masking, or combination products) can still extend market exclusivity for branded products.
• Chiral Synthesis: Ibuprofen is a chiral molecule, with the S-(+) enantiomer being the pharmacologically active form. While racemic ibuprofen (a 50:50 mixture of R and S enantiomers) is widely used, patents for enantioselective synthesis routes that produce predominantly the S-(+) form exist. These aim to reduce the metabolic load by avoiding the inactive R-(-) enantiomer, though the clinical benefit and economic viability of enantiomerically pure ibuprofen in mass-market OTC products have been debated [6].

The expiration of key patents for ibuprofen synthesis has led to a highly competitive generic market. This has driven down prices for the API and finished drug product, making ibuprofen one of the most accessible and affordable non-steroidal anti-inflammatory drugs (NSAIDs) globally. The primary competitive advantages for API manufacturers now lie in economies of scale, operational efficiency, raw material sourcing, and maintaining stringent quality and regulatory compliance.

How is Ibuprofen API Produced?

The most common industrial synthesis of ibuprofen is the Boots Process, a three-step synthesis that has been widely adopted and optimized. While variations exist, the core steps remain:

1. Friedel-Crafts Acylation: Isobutylbenzene is reacted with acetyl chloride in the presence of a Lewis acid catalyst, typically aluminum chloride (AlCl3), to form 4-isobutylacetophenone.
   • Reaction: Isobutylbenzene + Acetyl Chloride → 4-Isobutylacetophenone + HCl
   • Catalyst: AlCl3
   • Conditions: Typically carried out in a solvent like nitrobenzene or methylene chloride.
2. Darzens Glycidic Ester Condensation (or similar carbonylation): 4-Isobutylacetophenone is reacted with ethyl chloroacetate in the presence of a strong base, such as sodium ethoxide, to form an intermediate glycidic ester. This step introduces the crucial carboxylic acid precursor.
   • Reaction: 4-Isobutylacetophenone + Ethyl Chloroacetate + Base → Glycidic Ester Intermediate
   • Base: Sodium ethoxide (NaOEt)
3. Hydrolysis and Decarboxylation: The glycidic ester intermediate is hydrolyzed and decarboxylated, often under acidic or basic conditions, to yield ibuprofen.
   • Reaction: Glycidic Ester Intermediate → Ibuprofen + Ethanol + CO2

Variations and Optimizations:

• BHC (Hoechst) Process: An alternative, more environmentally friendly process was developed by BHC (now part of SI Group). This process is a six-step synthesis but is considered more atom-economical, generating less waste. It involves:
  1. Carbonylation of isobutylbenzene to form 4-isobutylacetophenone.
  2. Hydrogenation of 4-isobutylacetophenone to form the corresponding alcohol.
  3. Conversion of the alcohol to an ester.
  4. Hydroformylation to introduce the aldehyde group.
  5. Oxidation of the aldehyde to the carboxylic acid (ibuprofen).
     • This process uses hydrogen fluoride (HF) as a catalyst in the carbonylation step and palladium-based catalysts for hydrogenation and hydroformylation, aiming for higher yields and fewer byproducts compared to the original Boots process.
• Catalytic Improvements: Research continues to focus on developing more efficient and selective catalysts for each step, aiming to reduce catalyst loading, improve reaction rates, and minimize side reactions.
• Solvent Reduction/Replacement: Efforts are made to reduce the use of hazardous solvents or replace them with greener alternatives.

The choice of synthesis route by a manufacturer is often dictated by factors such as existing plant infrastructure, raw material availability and cost, patent freedom to operate, and environmental regulations.

What are the Regulatory Requirements for Ibuprofen API?

The production and sale of ibuprofen API are subject to stringent regulatory oversight to ensure patient safety and product quality. Key regulatory bodies and requirements include:

• Good Manufacturing Practices (GMP): Manufacturers must adhere to GMP guidelines established by regulatory agencies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the World Health Organization (WHO). GMP ensures that products are consistently produced and controlled according to quality standards [7]. This includes:
  • Facility and Equipment Qualification: Premises and equipment must be designed, maintained, and validated for their intended use.
  • Personnel Training: All personnel involved in manufacturing must be adequately trained.
  • Raw Material Control: Incoming raw materials must be tested and approved before use.
  • Process Validation: Manufacturing processes must be validated to ensure they consistently produce API meeting predefined specifications.
  • Quality Control Testing: API must undergo rigorous testing for identity, purity, potency, and other critical quality attributes.
  • Record Keeping: Comprehensive batch records and documentation are required for traceability.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory authorities (e.g., FDA, EMA). A DMF contains detailed information about the manufacturing process, facility, quality control, and stability of the API. Pharmaceutical companies seeking to use the API in their drug products can then reference the DMF in their drug applications, streamlining the approval process [8].
• Pharmacopoeial Standards: Ibuprofen API must comply with the specifications outlined in major pharmacopoeias, such as the United States Pharmacopeia (USP), the European Pharmacopoeia (Ph. Eur.), and the Japanese Pharmacopoeia (JP). These monographs define the quality, purity, and analytical testing methods for the API [9].
• Impurity Profiling: Regulatory agencies require manufacturers to identify, quantify, and control process-related impurities and degradation products. Specific impurity limits are often set based on toxicological data and guidances from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) [10].
• Environmental, Health, and Safety (EHS) Regulations: API manufacturing facilities must comply with local and international EHS regulations regarding chemical handling, waste disposal, emissions, and worker safety.

Compliance with these regulations is critical for API manufacturers to access global markets and maintain the trust of pharmaceutical companies and regulatory bodies. Regular inspections by health authorities ensure ongoing adherence to these standards.

What are the Global Trade Dynamics and Key Markets for Ibuprofen API?

The global trade in ibuprofen API is substantial, driven by the demand for both prescription and over-the-counter (OTC) ibuprofen formulations worldwide. Key dynamics include:

• Dominance of Generic Markets: The vast majority of ibuprofen is sold as a generic product, meaning that API manufacturers primarily supply generic drug manufacturers. This leads to significant price competition.
• Export-Oriented Production: Countries like China and India have become major exporters of ibuprofen API due to their large-scale production capacities and competitive cost structures. Their output serves global pharmaceutical markets, including North America, Europe, and emerging economies.
• Key Importing Regions:
  • North America (USA and Canada): High demand for OTC pain relief and anti-inflammatory products fuels significant API imports.
  • Europe: A mature pharmaceutical market with substantial consumption of ibuprofen, both for prescription and OTC use.
  • Asia Pacific: Growing healthcare expenditure and increasing access to medicines in countries like China, India, and Southeast Asian nations contribute to strong demand.
  • Latin America and Africa: These regions represent growing markets where affordable pain relief options like ibuprofen are in high demand.
• Supply Chain Resilience: Recent global events have highlighted the importance of supply chain resilience. Pharmaceutical companies are increasingly scrutinizing the geographic concentration of API production and may seek to diversify their supplier base to mitigate risks associated with geopolitical instability, trade disputes, or pandemics. This could potentially lead to a slight resurgence in API manufacturing in higher-cost regions for critical medications.
• Raw Material Sourcing: The availability and cost of key starting materials for ibuprofen synthesis (e.g., isobutylbenzene) also influence global trade patterns. Manufacturers often integrate backward or secure long-term contracts to ensure stable supply and competitive pricing.
• Quality and Regulatory Alignment: While cost is a major driver, API purchasers also prioritize suppliers who meet stringent quality standards and have established regulatory compliance. APIs from manufacturers with a strong regulatory track record (e.g., FDA-approved facilities) command a premium.

The market for ibuprofen API is mature and relatively stable, with growth primarily driven by population increases and the ongoing use of ibuprofen as a first-line analgesic and anti-inflammatory.

Key Takeaways

• The global ibuprofen API market is concentrated among a few major manufacturers, including BASF, SI Group, Hebei Jiheng Pharmaceutical, and IOL Chemicals and Pharmaceuticals.
• Production is geographically concentrated in Asia and Europe, with Asia being a dominant export hub due to cost advantages.
• The patent landscape for core ibuprofen synthesis methods has largely expired, fostering a competitive generics market. Current patent activity focuses on process optimization, polymorph control, and novel formulations.
• API production must adhere to strict GMP standards and pharmacopoeial requirements, with manufacturers typically filing Drug Master Files with regulatory agencies.
• Global trade dynamics are shaped by high demand for generic ibuprofen, with significant exports from China and India to North America, Europe, and emerging markets.
• Supply chain resilience is becoming a more critical factor for pharmaceutical companies, potentially influencing sourcing strategies.

Frequently Asked Questions

1. What is the primary difference between the Boots Process and the BHC Process for ibuprofen synthesis? The Boots Process is a three-step synthesis generally considered simpler but less atom-economical, producing more byproducts. The BHC (Hoechst) Process is a six-step synthesis that is more atom-economical, designed to reduce waste and environmental impact, though it uses specific catalysts like hydrogen fluoride.

2. Are there any active patents that prevent generic ibuprofen production? Patents covering the fundamental chemical synthesis routes for ibuprofen have largely expired. However, patents for specific process improvements, novel polymorphs, or specialized formulations can still provide market exclusivity for certain products or manufacturing methods.

3. What are the main quality control tests performed on ibuprofen API? Key tests include assays for potency, identification tests (e.g., infrared spectroscopy), tests for related substances and impurities, residual solvents, and physical characteristics like melting point and particle size distribution. Compliance with pharmacopoeial monographs (USP, Ph. Eur., JP) dictates specific test parameters.

4. How does the chirality of ibuprofen affect its production and use? Ibuprofen is a racemic mixture of S-(+) and R-(-) enantiomers. While the S-(+) form is pharmacologically active, racemic ibuprofen is widely used and regulated. Patents exist for enantioselective synthesis of S-(+)-ibuprofen, but cost and the established efficacy of the racemic mixture have limited its widespread adoption in generic OTC products.

5. What are the potential risks associated with the concentrated global supply of ibuprofen API? A concentrated supply chain can be vulnerable to disruptions from geopolitical events, natural disasters, or pandemics. Dependence on a few key manufacturers or regions can lead to supply shortages or price volatility if production is impacted.

Citations

[1] BASF SE. (n.d.). Active Pharmaceutical Ingredients. Retrieved from https://www.basf.com/global/en/markets/pharma/active-pharmaceutical-ingredients.html [2] SI Group. (n.d.). Pharmaceuticals. Retrieved from https://www.sigroup.com/markets/pharmaceuticals [3] Hebei Jiheng Pharmaceutical Co., Ltd. (n.d.). Products. Retrieved from https://www.jihengpharm.com/en/product.html (Note: Specific product pages may vary; general product information is presented.) [4] IOL Chemicals and Pharmaceuticals Ltd. (n.d.). Products - Ibuprofen. Retrieved from https://www.iolcp.com/products/ibuprofen [5] Chawla, G., & Sharma, P. (2017). Polymorphism of Ibuprofen: A Review. International Journal of Pharmaceutical Sciences and Research, 8(11), 4599-4608. [6] Williams, K. M., & Schimmer, B. P. (1990). Nonsteroidal antiinflammatory drugs. In Goodman & Gilman's The Pharmacological Basis of Therapeutics (8th ed.). Pergamon Press. [7] U.S. Food and Drug Administration. (n.d.). Good Manufacturing Practice (GMP). Retrieved from https://www.fda.gov/training-and-events/pharmaceutical-training/good-manufacturing-practice-gmp [8] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files [9] United States Pharmacopeial Convention. (n.d.). Pharmacopeias. Retrieved from https://www.usp.org/products/pharmacopeias [10] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). Harmonised Tripartite Guideline - Impurities: Guideline for Residual Solvents Q3C(R6).